Apyx Medical (APYX) closed at $2.55 on October 16, 2026, down 0.4% from the previous close, on volume of 53,857 shares (30-day average 141,445).
Data as of October 16, 2026.
16-Oct-2026
Apyx Medical Announces New Clinical Study Demonstrating Renuvion's Impact on Skin Quality
Globe Newswire (Tue, 29-Sep 8:00 AM ET)
Apyx Medical Corporation Reports Second Quarter 2026 Financial Results
Globe Newswire (Thu, 6-Aug 4:05 PM ET)
Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference
Globe Newswire (Tue, 28-Jul 8:00 AM ET)
Globe Newswire (Thu, 23-Jul 8:00 AM ET)
Market Chameleon (Thu, 4-Dec 6:55 AM ET)
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.
Apyx Medical trades on the NASDAQ stock market under the symbol APYX.
As of October 16, 2026, APYX stock price declined to $2.55 with 53,857 million shares trading.
APYX has a beta of -0.50, meaning it tends to be less sensitive to market movements. APYX has a correlation of 0.01 to the broad based SPY ETF.
APYX has a market cap of $107.38 million. This is considered a Micro Cap stock.
Last quarter Apyx Medical reported $14 million in Revenue and -$.07 earnings per share. This beat revenue expectation by $558,500 and exceeded earnings estimates by $.02.
In the last 3 years, APYX traded as high as $5.08 and as low as $.76.
The top ETF exchange traded funds that APYX belongs to (by Net Assets): VTI, VXF, IWC, BUSM, DFAC.
APYX has underperformed the market in the last year with a return of -18.0%, while the SPY ETF gained +16.7%. In the last 3 month period, APYX fell short of the market, returning -41.2%, while SPY returned +1.9%. However, in the most recent 2 weeks APYX has outperformed the stock market by returning 0.0%, while SPY returned -0.8%.
APYX support price is $2.43 and resistance is $2.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APYX shares will trade within this expected range on the day.
